Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult subjects, 18 years of age and over, who understand the risks and benefits of participation and have provided written informed consent for the study.~2. Subjects who are experiencing a first event or first recurrence of clostridium difficile (CDI) within the last 28 days and have been successfully treated with an antibiotic for CDI.~3. Subjects who are medically stable.~4. Subjects who are willing and able to comply with the study procedures and visit schedules outlined.~5. If female be post-menopausal, surgically sterile or agree to follow an acceptable method of birth control.~Exclusion Criteria:~1. Subjects who have had more than 2 episodes of CDI within the last 6 months.~2. Subjects who have been diagnosed with Inflammatory Bowel Disease,active Irritable Bowel Syndrome, celiac disease, active gastroparesis, toxic megacolon.~3. GI surgery within 6 weeks before the day of randomization~4. Have known immunodeficiency disorder, such as HIV Infection~5. Pregnant or breast feeding females.~6. Concurrent acute life-threatening diseases.~7. Inability to tolerate oral liquids.~8. Have an absolute neutrophil count \< 1000/mm3 at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- VP20621 Low Dose and Placebo (Type: EXPERIMENTAL): None
- VP20621 High Dose and Placebo (Type: EXPERIMENTAL): None
- VP20621 High Dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).